THE European Medicines Agency
has recommended changes to the
use of metoclopramide, including
restricting the dosage and duration
of use of the medicine (for short
term use up to five days) to
minimise “known risks of serious
neurological side effects”.
The EMA has also finalised a
review on GLP-1 (gliptin) therapies,
and concluded that presently
available data “do not confirm
recent concerns over an increased
risk of pancreatic adverse events
with these medicines”.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 13
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.